Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Autor: Stock CJW; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK. c.stock@imperial.ac.uk., De Lauretis A; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.; Unita' Operativa Malattie Respiratorie, Ospedale Guido Salvini, Garbagnate Milanese, Milan, Italy., Visca D; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.; Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy., Daccord C; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.; Division of Respiratory Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Kokosi M; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Kouranos V; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Margaritopoulos G; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., George PM; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Molyneaux PL; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Nihtyanova S; Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, London, UK., Chua F; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Maher TM; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Ong V; Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, London, UK., Abraham DJ; Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, London, UK., Denton CP; Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, London, UK., Wells AU; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK., Wain LV; Department of Health Sciences, University of Leicester, Leicester, UK.; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK., Renzoni EA; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.

Publikováno v: Clinical rheumatology [Clin Rheumatol] 2020 Apr; Vol. 39 (4), pp. 1173-1179. Date of Electronic Publication: 2020 Jan 08.

BELIMUMAB FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: A PHASE 2/3, RANDOMISED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL.

Autor: Denton, C. P., Spiera, R., Jörg, D., Khanna, D., Kreuter, M., Kuwana, M., Volkmann, E., Cotic, J., Raji, O., Hammer, A., Zeccin, C., Van Maurik, A., Olaiz, J. M., Fahy, W., Tomlinson, R., Dastros-Pitei, D., Nihtyanova, S., Irving, E., Maher, T.

Publikováno v: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p1668-1668, 1p